{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:19:41Z","timestamp":1790623181919,"version":"4.1.0"},"reference-count":58,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clusterin exerts anti-inflammatory, cytoprotective and anti-apoptotic effects. Both an increase and decrease of clusterin in acute myocardial infarction (AMI) has been reported. We aimed to clarify the role of clusterin as a systemic biomarker in AMI. AMI was induced by percutaneous left anterior artery (LAD) occlusion for 90 min followed by reperfusion in 24 pigs. Contrast ventriculography was performed after reperfusion to assess left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) and additional cMRI + late enhancement to measure infarct size and LV functions at day 3 and week 6 post-MI. Blood samples were collected at prespecified timepoints. Plasma clusterin and other biomarkers (cTnT, NT-proBNP, neprilysin, NGAL, ET-1, osteopontin, miR21, miR29) were measured by ELISA and qPCR. Gene expression profiles of infarcted and remote region 3 h (n = 5) and 3 days (n = 5) after AMI onset were analysed by RNA-sequencing. AMI led to an increase in LVEDV and LVESV during 6-week, with concomitant elevation of NT-proBNP 3-weeks after AMI. Plasma clusterin levels were increased immediately after AMI and returned to normal levels until 3-weeks. Plasma NGAL, ET-1 and miR29 was significantly elevated at 3 weeks follow-up, miR21 increased after reperfusion and at 3 weeks post-AMI, while circulating neprilysin levels did not change. Elevated plasma clusterin levels 120 min after AMI onset suggest that clusterin might be an additional early biomarker of myocardial ischemia.<\/jats:p>","DOI":"10.3390\/ijms21134591","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T05:28:56Z","timestamp":1593408536000},"page":"4591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early Elevation of Systemic Plasma Clusterin after Reperfused Acute Myocardial Infarction in a Preclinical Porcine Model of Ischemic Heart Disease"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8679-1525","authenticated-orcid":false,"given":"Denise","family":"Traxler","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-0361","authenticated-orcid":false,"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Einzinger","sequence":"additional","affiliation":[{"name":"Institute of Information Systems Engineering, Research Unit of Information and Software Engineering, Vienna University of Technology, 1040 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-6670","authenticated-orcid":false,"given":"Julia","family":"Mester-Tonczar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Lukovic","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Winkler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7643","authenticated-orcid":false,"given":"Katrin","family":"Zlabinger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-9967","authenticated-orcid":false,"given":"Alfred","family":"Gugerell","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubica","family":"Mandic","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2107","authenticated-orcid":false,"given":"Mariann","family":"Gy\u00f6ngy\u00f6si","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Pavo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/j.1552-4604.1986.tb03532.x","article-title":"Infarct size reduction: A review of the clinical trials","volume":"26","author":"Campbell","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"ref_2","first-page":"e28","article-title":"Heart disease and stroke statistics--2014 update: A report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","article-title":"Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFkappaB Pathway","volume":"70","author":"Buonafine","year":"2017","journal-title":"Hypertension"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.9778\/cmajo.20130074","article-title":"Performance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: Systematic review and meta-analysis","volume":"2","author":"Alazzoni","year":"2014","journal-title":"CMAJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays","volume":"361","author":"Reichlin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"102","article-title":"High-sensitive cardiac troponin T","volume":"10","author":"Xu","year":"2013","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1357-2725(01)00155-8","article-title":"Clusterin","volume":"34","author":"Jones","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0531-5565(02)00139-0","article-title":"Serum levels of the senescence biomarker clusterin\/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction","volume":"37","author":"Trougakos","year":"2002","journal-title":"Exp. Gerontol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0065-230X(09)04006-8","article-title":"Chapter 6 The Chaperone Action of Clusterin and Its Putative Role in Quality Control of Extracellular Protein Folding","volume":"104","author":"Wyatt","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/bmc-2015-0026","article-title":"The CLU-files: Disentanglement of a mystery","volume":"7","author":"Rohne","year":"2016","journal-title":"Biomol. Concepts"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI9037","article-title":"Apolipoprotein J\/clusterin limits the severity of murine autoimmune myocarditis","volume":"106","author":"McLaughlin","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1523-1747.1999.00531.x","article-title":"Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress","volume":"112","author":"Viard","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/pr100805h","article-title":"Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction","volume":"10","author":"Cubedo","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e004838","DOI":"10.1161\/CIRCHEARTFAILURE.117.004838","article-title":"Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction","volume":"11","author":"Turkieh","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-2143(98)90074-9","article-title":"Temporal induction of clusterin in the peri-infarct zone after experimental myocardial infarction in the rat","volume":"131","author":"Silkensen","year":"1998","journal-title":"J. Lab. Clin. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"H2193","DOI":"10.1152\/ajpheart.00355.2005","article-title":"Clusterin: A protective mediator for ischemic cardiomyocytes?","volume":"289","author":"Krijnen","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2362.2010.02345.x","article-title":"Intravenous clusterin administration reduces myocardial infarct size in rats","volume":"40","author":"Vermond","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bernelin, H., Mewton, N., Si-Mohamed, S., Croisille, P., Rioufol, G., Bonnefoy-Cudraz, E., Douek, P., Dufay, N., Amaz, C., and Jossan, C. (2018). Neprilysin levels at the acute phase of ST-elevation myocardial infarction. Clin. Cardiol.","DOI":"10.1002\/clc.23090"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A Test in Context: Neprilysin: Function, Inhibition, and Biomarker","volume":"68","author":"Barallat","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jchf.2015.03.006","article-title":"Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study","volume":"3","author":"Barallat","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","article-title":"Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients","volume":"65","author":"Barallat","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00365519409088436","article-title":"Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils","volume":"54","author":"Xu","year":"1994","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/eurheartj\/ehp088","article-title":"Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure","volume":"30","author":"Yndestad","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_25","first-page":"189797","article-title":"Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease","volume":"2012","author":"Kafkas","year":"2012","journal-title":"Int. J. Inflam."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2018.03.028","article-title":"Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is independently associated with mortality in patients with acute coronary syndrome","volume":"262","author":"Nymo","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gy\u00f6ngy\u00f6si, M., Pavo, N., Lukovic, D., Zlabinger, K., Spannbauer, A., Traxler, D., Goliasch, G., Mandic, L., Bergler-Klein, J., and Gugerell, A. (2017). Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. J. Transl. Med., 15.","DOI":"10.1186\/s12967-017-1299-0"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CRD.0b013e3181cfb646","article-title":"Osteopontin in cardiovascular disease: A potential therapeutic target","volume":"18","author":"Waller","year":"2010","journal-title":"Cardiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1054-8807(03)00042-5","article-title":"Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats","volume":"12","author":"Komatsubara","year":"2003","journal-title":"Cardiovasc. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1172\/JCI119031","article-title":"Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction","volume":"98","author":"Ashizawa","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lab.2004.08.007","article-title":"Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: Correlation with left-ventricular volume and function","volume":"145","author":"Suezawa","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/hrt.72.5.436","article-title":"Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: Relation to cardiovascular outcome","volume":"72","author":"Wieczorek","year":"1994","journal-title":"Br. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","article-title":"Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10741-010-9181-7","article-title":"Left ventricular remodeling in the post-infarction heart: A review of cellular, molecular mechanisms, and therapeutic modalities","volume":"16","author":"Gajarsa","year":"2011","journal-title":"Heart Fail. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","article-title":"Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis","volume":"105","author":"Sutherland","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41419-018-0805-5","article-title":"MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7","volume":"9","author":"Yang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7150\/ijms.4514","article-title":"MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis","volume":"9","author":"Qin","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/ATVBAHA.111.234286","article-title":"Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21","volume":"32","author":"Kumarswamy","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCRESAHA.110.228676","article-title":"Biogenesis and regulation of cardiovascular microRNAs","volume":"109","author":"Bauersachs","year":"2011","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/VHRM.S24509","article-title":"Troponin elevation in conditions other than acute coronary syndromes","volume":"7","author":"Tanindi","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wexler, Y., and Nussinovitch, U. (2020). The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis. Cells, 9.","DOI":"10.3390\/cells9040793"},{"key":"ref_46","first-page":"1","article-title":"Plasma miR-22-5p, miR-132-5p, and miR-150-3p Are Associated with Acute Myocardial Infarction","volume":"2019","author":"Li","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kumar, D., Narang, R., Sreenivas, V., Rastogi, V., Bhatia, J., Saluja, D., and Srivastava, K. (2020). Circulatory miR-133b and miR-21 as Novel Biomarkers in Early Prediction and Diagnosis of Coronary Artery Disease. Genes, 11.","DOI":"10.3390\/genes11020164"},{"key":"ref_48","first-page":"323","article-title":"Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction","volume":"20","author":"Zhang","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/emmm.201201749","article-title":"Early assessment of acute coronary syndromes in the emergency department: The potential diagnostic value of circulating microRNAs","volume":"4","author":"Oerlemans","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-0854.2007.00549.x","article-title":"Stress-Induced Retrotranslocation of Clusterin\/ApoJ into the Cytosol","volume":"8","author":"Nizard","year":"2007","journal-title":"Traffic"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"67227","DOI":"10.18632\/oncotarget.18438","article-title":"Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion","volume":"8","author":"Pavo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_52","first-page":"177","article-title":"Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction","volume":"80","author":"Vakeva","year":"1993","journal-title":"Immunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Pavo, N., Lukovic, D., Zlabinger, K., Zimba, A., Lorant, D., Goliasch, G., Winkler, J., Pils, D., Auer, K., and Jan Ankersmit, H. (2017). Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Sci. Rep., 7.","DOI":"10.1038\/srep43958"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jtcvs.2016.10.089","article-title":"Magnetic resonance imaging assessment of cardiac function in a swine model of hibernating myocardium 3 months following bypass surgery","volume":"153","author":"Swingen","year":"2017","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lukovic, D., Gugerell, A., Zlabinger, K., Winkler, J., Pavo, N., Baranyai, T., Giricz, Z., Varga, Z.V., Riesenhuber, M., and Spannbauer, A. (2019). Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020344"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:43:57Z","timestamp":1760175837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,28]]},"references-count":58,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21134591"],"URL":"https:\/\/doi.org\/10.3390\/ijms21134591","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,28]]}}}